Loading clinical trials...

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis | Clinical Trials | Clareo Health

UNKNOWNEARLY_PHASE1

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

NCT05493124•Beijing University of Chinese Medicine

View on ClinicalTrials.gov

Summary

To explore the efficacy and safety of "Manpixiao" in the treatment of Chronic Atrophic Gastritis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The age is 18-75 years old, regardless of gender;
•Before treatment, the patients were diagnosed as chronic atrophic gastritis (with intestinal metaplasia and dysplasia) by gastroscopy and pathological examination, which met the criteria of the Chinese consensus on chronic gastritis (2017, Shanghai);
•Sign the informed consent form.

Exclusion Criteria

•Patients with autoimmune gastritis (chronic atrophic gastritis type A), peptic ulcer (a1-h2), reflux esophagitis, gastric polyps, hypertrophic gastritis and other diseases;
•Patients with high-grade intraepithelial neoplasia of gastric mucosa, suspected malignant change of gastrointestinal mucosal lesions, and gastrointestinal tumors;
•Patients with malignant tumors who have undergone surgery, radiotherapy and chemotherapy in recent 5 years;
•Patients with primary diseases such as heart, brain, lung, hematopoietic system and malignant tumors, and subjects with severe diabetes;
•Patients with chronic liver and kidney dysfunction before treatment, including ALT \> 1.5 times the upper limit of normal value, blood creatinine (CR) \> 1.5 times the upper limit of normal value, and platelets lower than 1.5 times the lower limit of normal value;
•Disabled subjects specified by law (blind, deaf, dumb, intellectual, mental, physical disabilities);
•The description of self symptoms is unclear or the investigation is not the author;
•Have a history of alcohol abuse;
•Allergic constitution or a history of allergy to multiple drugs (more than two or known ingredients in the drug);
•Pregnant or lactating women;
+1 more criteria

Locations (3)

Dongfang Hospital, Beijing University of Chinese Medicine

Beijing, China

Dongzhimen Hospital, Beijing University of TCM

Beijing, China

Zaozhuang Hospital, Beijing University of Chinese Medicine

Beijing, China

Key Dates

Start Date

July 1, 2021

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

August 9, 2022

Enrollment

180

ESTIMATED participants

Conditions

Chronic Atrophic Gastritis

Interventions

Manpixiao

DRUG

Active comparator

DRUG

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

NCT03261934

Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation

View study

UNKNOWN

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

NCT05388890

Chronic Atrophic Gastritis

View study

UNKNOWN

Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

Inclusion Criteria

Exclusion Criteria

Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation

Clinical Study of Weifuchun Treatment on Precancerous Lesions of Gastric Cancer

Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)

To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)